-
PROVIDERS
Watch now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
ENROLL NOW
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications.Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Content
-
Videos
Transforming R&D with Generative AI and Real-World Data
Ryan Fukushima, Chief Operating Officer at Tempus, and Robert Shoemaker, Ph.D., Senior Vice President of Research at Erasca, Inc., spoke about the transformative power of artificial intelligence in oncology research and drug development at the AACR Annual Meeting 2025. -
WebinarsAI & ML in action: Demonstrating real-world impact in trial design & patient care
Discover how the Tempus platform leverages AI and ML to inform standard of care practices through health equity guidelines and drive insights that help refine clinical trial design. -
WebinarsThe RNA advantage: A multimodal approach to accelerating oncology R&D
Discover how transcriptomic data and multi-omics data integrated with AI is helping revolutionize oncology drug development and patient care and fueling precision medicine 2.0. Learn about RNA sequencing’s role in companion diagnostics and Tempus Loop’s capabilities to support target identification and validation. -
ArticlesQ&A: Harnessing generative AI to refine clinical research & drug development
Maria Berezine, VP of Real World Data at Tempus, recently led a webinar with leaders across healthcare and life sciences to discuss the impact generative AI tools have on maximizing the value of multimodal data. -
ArticlesQ&A: Integrating MRD and IO Monitoring with the Tempus portfolio: An oncologist’s perspective
This Q&A article features a discussion between Dr. Allan Espinosa of Arizona Oncology and Dr. Ezra Cohen, Chief Medical Officer at Tempus, exploring the practical application of Tempus’ tumor-naive and tumor-informed MRD and IO treatment monitoring portfolio in clinical practice. -
ArticlesQ&A: Connecting real-world data and organoids through Tempus Loop
Tim Hagerty, Ph.D, VP, Life Science Strategy at Tempus, discusses Tempus Loop, a platform aimed at enhancing target identification and validation by connecting real-world data with patient-derived organoids. He explains how this integrated approach overcomes limitations in traditional methods and its potential to accelerate preclinical development in oncology. -
ArticlesQ&A: Advancing early detection in lung cancer: The role of incidental pulmonary nodules
Insights into the impact of IPN management on patient outcomes -
ArticlesQ&A: How cutting-edge technologies are helping to advance precision medicine
In a recent webinar, Tempus leaders showcased how AI and ML-enabled technologies are revolutionizing the healthcare field and transforming precision, offering a glimpse into the future of healthcare innovation. -
Case StudiesDevelopment of a clinical algorithm to prognosticate response to immunotherapy
Discover how Tempus developed and deployed the Immune Profile Score (IPS)—a powerful algorithm that provides prognostic insights into patient outcomes following treatment with immune checkpoint inhibitors (ICIs)—in ~18 months. This case study highlights the AI-driven methodology, real-world validation, and the impact of IPS in precision oncology. -
Webinars
AI & ML in action: Unlocking RWD with GenAI through Tempus Lens
Discover how Tempus is equipping researchers with innovative AI solutions to fully leverage the potential of multimodal data. Gain insights from a panel of leaders across healthcare and life sciences as they discuss the impact of these advanced tools on delivering insights with speed. -
ArticlesQ&A: Navigating the future of IO: Biomarkers, combination therapies, and clinical strategies
In a recent webinar hosted by Tempus, industry experts gathered to discuss the latest in immuno-oncology (IO), where the cancer research landscape is ever-evolving due to the potential of emerging therapies. -
Case StudiesCase Report: Pharmacogenomic testing and mood stabilizers
This real-world case demonstrates how the Tempus nP pharmacogenomic test facilitated a personalized treatment approach for a patient with bipolar disorder. -
Case StudiesAdvancing precision medicine in the community setting with TIME and Next at Cancer and Blood Specialty Clinic
Discover how Cancer and Blood Specialty Clinic, a community oncology network, utilized Tempus TIME to expedite clinical trial enrollment and is expanding their impact on patient care with Tempus Next, an AI-enabled care pathway platform. -
ArticlesOncology innovation: How emerging biotechs lead through RWD & AI
Ryan Fukushima, Chief Operating Officer at Tempus, discusses how cutting-edge tools are helping biotechs streamline clinical trials, optimize patient selection, and improve decision-making, even amidst challenging market conditions. -
Webinars
AI & ML in action: Real-time advances in precision medicine
Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. -
ArticlesQ&A: Exploring the implications of CHIP on oncology patient care
In this Q&A, Dr. Ezra Cohen, Chief Medical Officer of Oncology, discusses key considerations and implications of clonal hematopoiesis of indeterminate potential (CHIP) for oncologists, focusing on its impact on genetic testing, diagnosis, and treatment decisions to help clinicians provide the best possible care for patients. -
ArticlesQ&A: Navigating the outcomes research landscape
Tempus’ Senior Director and Head of Strategy, HEOR, Emilie Scherrer, MSc, recently led a webinar with industry experts to discuss the evolving landscape of outcomes research, focusing on real-world evidence (RWE) and advanced analytics. -
Case StudiesAddressing health disparities at a large academic medical center: AI-driven cardiac care for aortic stenosis and mitral regurgitation
Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked. -
Webinars
Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies
Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer.
